KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Amgen's Depreciation & Amortization (CF) fell 637.54% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year decrease of 256.5%. This contributed to the annual value of $5.6 billion for FY2024, which is 3736.18% up from last year.
  • Per Amgen's latest filing, its Depreciation & Amortization (CF) stood at $1.3 billion for Q3 2025, which was down 637.54% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Amgen's Depreciation & Amortization (CF) registered a high of $1.4 billion during Q2 2024, and its lowest value of $828.0 million during Q2 2022.
  • Over the past 5 years, Amgen's median Depreciation & Amortization (CF) value was $900.0 million (recorded in 2023), while the average stood at $1.1 billion.
  • As far as peak fluctuations go, Amgen's Depreciation & Amortization (CF) tumbled by 806.45% in 2021, and later skyrocketed by 5625.0% in 2024.
  • Quarter analysis of 5 years shows Amgen's Depreciation & Amortization (CF) stood at $852.0 million in 2021, then rose by 6.92% to $911.0 million in 2022, then surged by 51.48% to $1.4 billion in 2023, then grew by 1.23% to $1.4 billion in 2024, then fell by 6.44% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.4 billion during Q1 2025.